Clinical Trials Brief | July 20, 2026
This week: EBO-PEP launching the first trial of post-exposure prophylaxis against Bundibugyo Ebola, FDA finalising its psychedelic trial guidance three years after the draft, EMA publishing ICH E6(R3) Annex 2 with a 15 January 2027 effective date, EU and UK healthcare professionals receiving new avacopan safety letters, and AstraZeneca licensing a China-discovered lung cancer drug for up to $1.5 billion.
EBO-PEP launches the first trial of post-exposure prophylaxis against Bundibugyo Ebola, two weeks after the treatment trial
What changed
On July 14, 2026, the INRB in Kinshasa, ANRS Emerging Infectious Diseases/Inserm and the NGO ALIMA launched EBO-PEP, the first clinical trial to assess oral obeldesivir (Gilead) as post-exposure prophylaxis against the Bundibugyo virus, in the Democratic Republic of the Congo and Uganda. Recruitment started at prophylaxis centres next to ALIMA's Ebola treatment centres in Bunia and Rwampara, in Ituri province. The trial aims to enrol nearly 1,000 adults and children over 12 who had direct contact with a confirmed case within the previous five days and have no symptoms. Participants are monitored daily for 21 days, with a final visit at day 42. A second sub-protocol will provide remdesivir on a compassionate-use basis to children under 12 and pregnant or breastfeeding contacts, because data on obeldesivir in those groups are insufficient. As of July 9, the DRC's National Institute of Public Health reported 1,759 infections and 600 deaths.
Why it matters
Combined with PARTNERS, which opened on July 2 to test treatments, the Bundibugyo response now has trials for both treatment and prevention running during the outbreak. That is the outcome outbreak-research reform has been aiming for. EBO-PEP shows why preparedness matters: the platform protocol has been in preparation since 2024 for several African countries, and a field training course on safety reporting, data management and monitoring was run in Bunia from June 30 to July 4. Funding came from EU Global Health EDCTP3, Africa CDC and, following a July 2 meeting in Kinshasa, the governments of the DRC and South Africa.
Takeaway
The design choice to separate an efficacy sub-protocol from a compassionate-use sub-protocol for populations without adequate data is a practical template for emergency trials, keeping the randomised question clean without leaving vulnerable contacts unprotected. Enrolment speed against the outbreak curve will decide whether EBO-PEP can answer its question.
Sources
This item is grounded in the ANRS MIE press release of July 14, 2026.
FDA finalises its psychedelic trial guidance three years after the draft, keeping a high evidentiary bar and announcing a public hearing
What changed
On July 13, 2026, FDA finalised Psychedelic Drugs: Considerations for Clinical Investigations, replacing the June 2023 draft; the Federal Register notice followed on July 14. The guidance covers chemistry and manufacturing, nonclinical work, clinical pharmacology, abuse potential, and trial design and safety. RAPS reported that FDA received more than 200 comments on the draft, with stakeholders raising concerns about separating drug administration from psychotherapy support, the credentials proposed for lead safety monitors, and how abuse potential is characterised. Both versions say the lead in-session monitor should be an independently licensed healthcare provider with graduate-level training and clinical experience in psychotherapy. According to King & Spalding, the final text newly encourages innovative approaches to control groups and accepts new approach methodologies and computational modelling as supportive data. FDA also announced a public hearing on the potential future therapeutic use of psychedelic drugs for September 14, 2026.
Why it matters
Functional unblinding is the central methodological problem in psychedelic trials: participants and raters can usually tell who received the active drug, which inflates effect sizes. FDA had previously signalled concern about this, and the final guidance keeps a demanding framework while giving sponsors more room on control-group design. King & Spalding describe it as reading like an approval-readiness document, with detailed expectations on abuse-potential assessment, scheduling and post-marketing measures. In my reading, this signals that FDA intends to approve psychedelics only through rigorously designed programmes, not through a lowered bar.
Takeaway
Sponsors with psychedelic programmes should re-check protocols written against the 2023 draft, especially control-arm design, blinding-integrity assessments and monitor qualifications. Sites need to plan staffing for licensed, psychotherapy-trained monitors, which is often the real bottleneck in recruitment capacity.
Sources
This item is grounded in RAPS reporting of July 13, 2026 and analysis from King & Spalding and the National Law Review.
EMA publishes ICH E6(R3) Annex 2 for the EU, with a 15 January 2027 effective date for decentralised, pragmatic and RWD trials
What changed
EMA has published the EU Step 5 version of ICH E6(R3) Annex 2 (document dated 13 July 2026). The cover page records final CHMP adoption on 25 June 2026 and a date for coming into effect of 15 January 2027. EMA's E6 page states that Annex 2 reached Step 4 following ICH adoption on 3 June 2026 and that a consolidated version of the E6(R3) principles, Annex 1 and Annex 2 has been published. The principles and Annex 1 have applied in the EU since 23 July 2025. Annex 2 adds GCP considerations for trials with decentralised elements, pragmatic designs and real-world data.
Why it matters
This brief covered ICH's adoption of Annex 2 on June 15. The EU publication turns it into a dated obligation for sponsors, investigators and inspectors in the EU, giving about six months to prepare. A single consolidated document also helps in practice: quality systems and training can now reference one E6(R3) text instead of piecing together the principles, Annex 1 and Annex 2 from separate documents. For trials that started under the existing framework, the transition question will be how inspectors treat decentralised activities conducted before January 2027.
Takeaway
Teams running hybrid or decentralised trials in the EU should use the time before 15 January 2027 to update SOPs, vendor oversight plans for home-health and direct-to-participant providers, and data-flow documentation for real-world data sources. Inspection readiness for 2027 should include an Annex 2 gap assessment in the trial master file.
Sources
This item is grounded in EMA's Step 5 publication of ICH E6(R3) Annex 2 and EMA's ICH E6 scientific guideline page.
EU and UK prescribers receive new avacopan letters: stop new starts, and monitor the liver more closely, including after stopping
What changed
On July 16, 2026, a direct healthcare professional communication (DHPC) agreed with EMA was distributed in the EU following CHMP's June recommendation to revoke Tavneos (avacopan). It tells prescribers that no new patients should start Tavneos, asks them to contact patients currently receiving it, and reinforces liver monitoring because of additional cases of drug-induced liver injury and vanishing bile duct syndrome, including fatal cases. Liver function must continue to be monitored after treatment stops. EMA's revocation notice specifies testing at least every two weeks until three months from the start of treatment for patients treated for under three months, and every four weeks for up to six months for those treated longer. In the UK, where the product is now called Avacopan Vifor, a separate DHPC dated July 2026 sets out updated liver-monitoring requirements and stopping rules, and states that no new patients should start treatment while the MHRA review of the benefits and risks of avacopan is ongoing.
Why it matters
This brief has followed avacopan since May. The July letters show two distinct issues being handled together: data integrity in the pivotal ADVOCATE trial, which undermines the efficacy case, and a hepatotoxicity signal that persists after stopping. The second point is clinically important. Clinicians switching patients off avacopan cannot simply discontinue and move on; liver monitoring has to continue. The renaming and separate review in the UK also show regulatory divergence after Brexit, even when the underlying concern is the same.
Takeaway
Investigators with patients on avacopan in other trials, or using it as background therapy in vasculitis studies, should update protocols for post-discontinuation liver monitoring and document it in source. Safety teams should treat any hepatic event in patients with recent avacopan exposure as potentially related, even weeks after the last dose.
Sources
This item is grounded in the EU DHPC on Tavneos disseminated on July 16, 2026, EMA's revocation notice, and the UK DHPC on Avacopan Vifor published by MHRA.
AstraZeneca licenses Dizal's sunvozertinib for up to $1.5 billion, its second China-sourced asset in a month
What changed
On July 14, 2026, Dizal announced a global exclusive license granting AstraZeneca worldwide rights to develop and commercialise Zegfrovy (sunvozertinib), an oral irreversible EGFR inhibitor. AstraZeneca pays $600 million upfront and up to $900 million in development, regulatory and sales milestones, plus tiered royalties. Zegfrovy is approved in the US and China for adults with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations whose disease progressed on or after platinum-based chemotherapy. Dizal has filed in both countries for first-line use based on the positive global Phase 3 WU-KONG28 trial. Pharmaceutical Technology reported about $83.4 million in 2025 sales, up 85% year on year, and described this as AstraZeneca's second licensing deal in China within a month. In the same week, on July 15, GSK completed its acquisition of Nuvalent.
Why it matters
This is a revenue-generating, already-approved asset with a pending first-line expansion, not an early-stage bet, which shows how far China-originated assets have moved up the value chain. For clinical development, the global WU-KONG28 trial is the important piece: a Chinese sponsor running a global Phase 3 that supports filings in both the US and China. That raises a question that Operation TrialBlazer, covered here on June 29, is trying to address from the other side: where pivotal and early-phase evidence is being generated, and which regulators are seeing it first.
Takeaway
Sites and CROs should expect global Phase 3 programmes for China-originated assets to transfer to Western sponsors mid-development more often. When that happens, plan for sponsor-transfer activities (TMF reconciliation, safety database migration, and updated agreements) as a defined workstream, not an afterthought.
Sources
This item is grounded in Dizal's press release of July 14, 2026, AstraZeneca's Q2 2026 filing, and Pharmaceutical Technology reporting.